Journal de mycologie medicale最新文献

{"title":"Identification, molecular characterization, and antifungal susceptibility of Cyberlindnera fabianii strains isolated from urinary tract","authors":"Fatma Mutlu Sariguzel ,&nbsp;Gamze Kalin Unuvar ,&nbsp;Osman Kucukoglu ,&nbsp;Omur Mustafa Parkan ,&nbsp;Ayse Nedret Koc","doi":"10.1016/j.mycmed.2023.101429","DOIUrl":"10.1016/j.mycmed.2023.101429","url":null,"abstract":"<div><h3>Objectives</h3><p><em>Cyberlindnera fabianii</em> is an opportunistic pathogen isolated from clinical specimens. It can be incorrectly identified as <em>Candida utulis</em> by phenotypic methods. This study aimed to accurately identify <em>Cy.fabianii</em> strains isolated from the urinary tract, and to determine their molecular characterization and antifungal susceptibilities as well.</p></div><div><h3>Methods</h3><p>Twenty-nine yeast strains isolated from urinary tract samples were studied. Strains were identified by phenotypically, sequence analysis and MALDI-TOF MS. Sequence analysis using different gene regions (ITS1-2,D1/D2,EF-1-alpha) in ribosomal DNA was performed for the molecular analysis. Phylogenetic analysis was done by the neighbor-joining method. Antifungal susceptibilities of strains were determined for nine antifungals by reference broth microdilution and the Sensititre YeastOne broth microdilution method (Sensititre^TMYeastOne^TMAST Plate, Thermo Fisher Scientific™,USA) according to CLSI M60-Ed2 recommendations.</p></div><div><h3>Results</h3><p>All strains were identified as <em>C.utulis</em> phenotypically by conventional methods, however all strains were identified as <em>Cy.fabianii</em> by sequence analysis and MALDI-TOF MS. It was observed that the gene regions examined in terms of determining evolutionary relatedness did not show intraspecies nucleotide variations. In all strains, the MIC50/MIC90 values for fluconazole were higher than the other antifungals tested.</p></div><div><h3>Conclusion</h3><p><em>Cy.fabianii</em> should be considered in fluconazole-resistant urinary tract yeast infections. Although conventional phenotypical methods were insufficient to identify <em>Cy.fabianii,</em> it could be correctly identified with sequence analysis using different gene regions (ITS1-2,D1/D2,EF-1-alpha) in ribosomal DNA and MALDI-TOF MS.</p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"33 4","pages":"Article 101429"},"PeriodicalIF":3.6,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10187039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of antifungal susceptibility and sequence types within Cryptococcus neoformans VNI from HIV patients, and ERG11 gene polymorphism","authors":"Bive Zono Bive ,&nbsp;Rosalie Sacheli ,&nbsp;Celestin Nzanzu Mudogo ,&nbsp;Pius Kabututu Zakayi ,&nbsp;Sébastien Bontems ,&nbsp;Georges Mvumbi Lelo ,&nbsp;Marie-Pierre Hayette","doi":"10.1016/j.mycmed.2023.101428","DOIUrl":"10.1016/j.mycmed.2023.101428","url":null,"abstract":"<div><h3>Introduction</h3><p><span>Here we tested the correlation between minimum inhibitory concentrations (MICs) of major antifungal agents and sequence types (STs) within </span><span><em>Cryptococcus neoformans</em></span> VNI isolates, and explored the <em>ERG11</em> gene of included strains.</p></div><div><h3>Materials and methods</h3><p>We analysed 23 <em>C. neoformans</em> strains categorised into two groups according to the distribution of the ST profile in Kinshasa clinics (Democratic Republic of Congo): major ST [ST93 (<em>n</em> = 15)], and less common STs [ST659 (<em>n</em> = 2), ST5 (<em>n</em> = 2), ST4 (<em>n</em> = 1), ST 53 (<em>n</em> = 1), ST31 (<em>n</em> = 1), and ST69 (<em>n</em><span> = 1)]. The MICs of the major antifungal agents [amphotericin B (AMB), 5-fluorocytosine (5FC) and fluconazole<span> (FCZ)] were determined following EUCAST guidelines. </span></span><em>ERG11</em> gene sequences were extracted from whole genome sequence of the isolates and compared with the wild-type gene sequence of the <em>C. neoformans</em> VNI.</p></div><div><h3>Results</h3><p>Although major ST isolates appeared to have lower median MICs for AMB and 5FU than less common ST isolates (0.50 vs. 0.75 mg/L for AMB, 2 vs. 4 mg/L for 5FU, respectively), FCZ susceptibility was similar in both groups (4 mg/L) (<em>p</em>-value &gt;0.05). The susceptibility profile of <em>C. neoformans</em> strains separately considered did not significantly affect the patients’ clinical outcomes (<em>p</em>-value &gt;0.05). Furthermore, two structural modalities of the <em>ERG11</em> gene were observed: (1) that of the reference gene, and (2) that containing two exonic silent point substitutions, and one intronic point substitution located in a sequence potentially involved in pre-mRNA splicing (c.337-22C &gt; T); with no association with the MICs of the isolates (<em>p</em>-value &gt;0.05).</p></div><div><h3>Conclusions</h3><p>The lack of association/correlation found in this study calls for further investigations to better understand the mechanisms of <em>C. neoformans</em> resistance to antifungal agents.</p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"33 4","pages":"Article 101428"},"PeriodicalIF":3.6,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10483309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fatal panresistant Lomentospora prolificans fungemia in a patient with aplastic anemia: First report from Türkiye","authors":"Zeynep Yazgan ,&nbsp;Tansu Dündar ,&nbsp;Ayşe Barış ,&nbsp;Özge Aksu ,&nbsp;Ahmet Emre Eşkazan ,&nbsp;Fatma Köksal Çakırlar","doi":"10.1016/j.mycmed.2023.101416","DOIUrl":"10.1016/j.mycmed.2023.101416","url":null,"abstract":"<div><p><span><em>Lomentospora prolificans</em></span><span><span> is an opportunistic pathogen<span> that can cause invasive lomentosporiosis in immunocompromised patients. Patients with </span></span>hematological malignancies<span> and those who have undergone stem cell or solid organ transplantations are in the highest risk group. In addition to the limitations and delays in diagnostic possibilities, </span></span><em>L. prolificans</em><span><span> has a high mortality due to its resistance to all available antifungal drugs. In a patient diagnosed with </span>aplastic anemia, we described the first case of </span><em>L. prolificans</em> in Türkiye. <em>L. prolificans</em><span> was identified in the blood culture, and despite the initiation of antifungal treatments<span>, the fungemia resulted in mortality on the 7th day of intensive care hospitalization. This case highlights the importance of early recognition and prompt initiation of appropriate antifungal therapy to improve the outcome of patients with rare mold infections.</span></span></p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"33 4","pages":"Article 101416"},"PeriodicalIF":3.6,"publicationDate":"2023-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9946295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Withdrawal notice to “Changes in the fungal nomenclature: why and how to manage?” [J Mycol Med 33 (2023) 101387]","authors":"C. Hennequin ,&nbsp;A. Coste ,&nbsp;C. Imbert","doi":"10.1016/j.mycmed.2023.101405","DOIUrl":"10.1016/j.mycmed.2023.101405","url":null,"abstract":"","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"33 3","pages":"Article 101405"},"PeriodicalIF":3.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10070316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Four uncommon clinical fungi, Lodderomyces elongisporus, Kodamaea ohmeri, Cyberlindnera fabianii and Wickerhamomyces anomalus, isolated in superficial samples from Côte d'Ivoire","authors":"Ama Valérie Bonouman Ira ,&nbsp;Donika Krasteva ,&nbsp;Francis Kouadjo ,&nbsp;Fréderic Roger ,&nbsp;Virginie Bellet ,&nbsp;David Koffi ,&nbsp;Cyrille Pottier ,&nbsp;Offianan André Toure ,&nbsp;Pascal Drakulovski ,&nbsp;Aliko Joseph Djaman ,&nbsp;Stéphane Ranque ,&nbsp;Sébastien Bertout","doi":"10.1016/j.mycmed.2023.101410","DOIUrl":"10.1016/j.mycmed.2023.101410","url":null,"abstract":"<div><h3>Aims</h3><p>The rare yeast species <span><em>Lodderomyces elongisporus, Kodamaea ohmeri, </em><em>Cyberlindnera</em><em> fabianii,</em></span> and <span><em>Wickerhamomyces anomalus</em></span><span> are increasingly implicated in severe mycoses<span> in immunocompromised patients. This study aimed to assess the prevalence of uncommon yeast species in Côte d'Ivoire.</span></span></p></div><div><h3>Methods</h3><p>The yeast isolates from superficial samples, mainly vaginal swabs, were collected at the Pasteur Institute of Abidjan in a study on the molecular epidemiology<span> of clinical yeast species. Identification relied on MALDI-TOF MS and ITS sequence analysis. Antifungal susceptibility testing was performed using the CLSI method.</span></p></div><div><h3>Results</h3><p>Of the 315 strains analysed from 227 outpatients, 14 belonged to 4 uncommon species: <em>Lodderomyces elongisporus, Kodamaea ohmeri, Cyberlindnera fabianii,</em> and <em>Wickerhamomyces anomalus</em><span><span><span>. None exhibited elevated fluconazole, </span>amphotericin B, </span>caspofungin, ketoconazole, or flucytosin MIC.</span></p></div><div><h3>Conclusions</h3><p>The presence of these rare yeasts represents a risk in immunocompromised people. Their adequate and timely identification is a priority. Overall, enhancing the mycoses diagnostic capacities in Côte d'Ivoire, and more generally in African clinical laboratories with limited resources is a critical aim.</p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"33 3","pages":"Article 101410"},"PeriodicalIF":3.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10078344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ibrutinib and tracheal mucormycosis: A case report and systematic review of literature","authors":"Vikram Damaraju ,&nbsp;Ritesh Agarwal ,&nbsp;Inderpaul Singh Sehgal ,&nbsp;Alka Khadwal ,&nbsp;Amanjit Bal ,&nbsp;Shivaprakash Mandya Rudramurthy ,&nbsp;Valliappan Muthu","doi":"10.1016/j.mycmed.2023.101414","DOIUrl":"10.1016/j.mycmed.2023.101414","url":null,"abstract":"<div><p><span><span><span>Ibrutinib, a </span>Bruton tyrosine kinase (BTK) inhibitor, has been approved for various </span>hematological malignancies<span><span>. Invasive aspergillosis is a known complication of ibrutinib, but </span>mucormycosis<span><span> is rare. We describe the case of a 70-year-old man with mantle cell lymphoma<span> infiltrating the trachea, managed with a tracheobronchial stent and ibrutinib. He had improved one month after treatment, and we removed the airway stent. Four months later, he developed tracheal nodules confirmed to be tracheal mucormycosis and responded to liposomal </span></span>amphotericin B (3.5 g) followed by </span></span></span>posaconazole<span>. After transient improvement, the tracheal lesions recurred, the biopsy showed lymphoma (with no evidence of mucormycosis), and he died. A systematic review of the literature identified 20 additional cases of ibrutinib-associated mucormycosis. Most of the 21 patients included were men (95%), and ibrutinib was the only risk factor in 15.7%. The reported mortality was 31.6% (6/19), attributable to mucormycosis in half the cases.</span></p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"33 3","pages":"Article 101414"},"PeriodicalIF":3.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10079438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19-associated mucormycosis in India: Why such an outbreak?","authors":"Gregoire Pasquier","doi":"10.1016/j.mycmed.2023.101393","DOIUrl":"10.1016/j.mycmed.2023.101393","url":null,"abstract":"<div><p>An unprecedented mucormycosis outbreak occurred in India during the second COVID-19 wave in spring 2021. COVID-19-associated mucormycosis (CAM) was observed, mainly rhino-orbito-cerebral mucormycosis (ROCM), in patients with poorly controlled diabetes and treated with inappropriate doses of glucocorticoids. The aim of this mini-review was to compare the characteristics of the CAM epidemic in India with (i) mucormycosis cases before the COVID-19 pandemic and (ii) CAM in the rest of the world (particularly in France) in order to identify the reasons for this outbreak. In India, the major mucormycosis epidemiologic change during the COVID-19 pandemic was an increase in the percentage of patients treated with corticosteroids who developed CAM. Compared with the rest of the world, India reported a higher mucormycosis incidence even before the COVID-19 pandemic. Moreover, in India, patients with CAM were more likely to have diabetes mellitus and ROCM; conversely, mortality rates were lower. The reasons for such a localized epidemic in India have remained unclear, but some hypotheses can be put forward, particularly the combination of high prevalence of uncontrolled diabetes mellitus and frequent indiscriminate corticosteroid utilization in a country that already had a high mucormycosis burden before the COVID-19 pandemic.</p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"33 3","pages":"Article 101393"},"PeriodicalIF":3.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10132753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interest of a metabolic approach using the calScreener™ technology to detect Candida in the peritoneal fluid: A pilot study","authors":"Emmanuel Novy ,&nbsp;Marie Collot ,&nbsp;Paul Chevallier ,&nbsp;Lisiane Cunat ,&nbsp;Marie Machouart","doi":"10.1016/j.mycmed.2023.101418","DOIUrl":"10.1016/j.mycmed.2023.101418","url":null,"abstract":"","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"33 4","pages":"Article 101418"},"PeriodicalIF":3.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9946297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cryptococcal meningitis in a non-HIV patient with solid organ transplantation","authors":"Mediha Ugur ,&nbsp;Sinan Cetin ,&nbsp;Emel Uzunoglu ,&nbsp;Mustafa Saglam ,&nbsp;Fatma Mutlu ,&nbsp;Ayse Nedret Koc","doi":"10.1016/j.mycmed.2023.101388","DOIUrl":"10.1016/j.mycmed.2023.101388","url":null,"abstract":"<div><p><span>Cryptococcal meningitis (CM) is often associated with human immunodeficiency virus (HIV). Recently, this microorganism has been increasingly identified in HIV-negative patients. CM cases are encountered in HIV-negative individuals, especially secondary to liver disease, </span>solid organ transplantation<span><span> (SOT), tuberculosis, lymphoproliferative diseases with T-cell-mediated immunological disorders, long-term corticosteroid use, </span>malignancies<span>, diabetes mellitus, and sarcoidosis<span>. Our patient is an HIV-negative, SOT case with CM. It should be considered that CM can also occur in HIV-negative patients. As in our case, patients receiving long-term immunosuppressive therapy<span> should be evaluated for CM, and renal functions should be closely monitored during treatment. There is a need for more case reports on the subject, especially in CM detected HIV-negative patients, due to the different treatment protocols and challenging clinical conditions compared to HIV-positive cases.</span></span></span></span></p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"33 3","pages":"Article 101388"},"PeriodicalIF":3.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10067806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fungemia due to rare non-Candida yeasts between 2018 and 2021 in a Greek tertiary care university hospital","authors":"Anastasia Spiliopoulou ,&nbsp;Alexandra Lekkou ,&nbsp;Georgia Vrioni ,&nbsp;Lydia Leonidou ,&nbsp;Massimo Cogliati ,&nbsp;Myrto Christofidou ,&nbsp;Markos Marangos ,&nbsp;Fevronia Kolonitsiou ,&nbsp;Fotini Paliogianni","doi":"10.1016/j.mycmed.2023.101386","DOIUrl":"10.1016/j.mycmed.2023.101386","url":null,"abstract":"<div><h3>Introduction</h3><p>Non-<em>Candida</em> yeasts, although rare, are increasingly encountered and recognized as a growing threat.</p></div><div><h3>Methods</h3><p>Cases of bloodstream infections (BSIs) due to non-<em>Candida</em> yeasts (NCYs) during the last four years (2018–2021) are presented.</p></div><div><h3>Results</h3><p>During the study period, 16 cases caused by non-<em>Candida</em> yeasts out of 400 cases of yeast BSIs were recorded, corresponding to an incidence of 4%. Yeasts that were isolated included <em>Cryptococcus</em> spp (4 isolates-25%), <em>Rhodotorula mucilaginosa</em> (2 isolates-12.5%), <em>Trichosporon asahii</em> (7 isolates-43.75%) and <em>Saccharomyces cerevisiae</em> (3 isolates-18.75%). Predisposing factors involved mostly hematological malignancies, long term hospitalization or major surgical interventions. Most isolates, 15 out of 16 were susceptible to amphotericin B. Voriconazole was the most active azole in vitro. All isolates, except <em>Saccharomyces</em> spp., were resistant to echinocandins.</p></div><div><h3>Discussion</h3><p>Early recognition of rare yeasts as causative agents of BSIs and prompt initiation of appropriate treatment based on current guidelines and expertise remain crucial in efficient patient management.</p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"33 3","pages":"Article 101386"},"PeriodicalIF":3.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10077740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}